Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also developed an antibody cocktail for COVID-19, REGEN-COV. REGEN-COV is a cocktail of two monoclonal antibodies and was designed specifically to block the infectivity of SARS-CoV-2, the virus that causes COVID-19. Regeneron has a collaboration agreement with Roche for the same. While Regeneron has co-developed Eylea with Bayer's HealthCare unit, Praluent was co-developed with Sanofi. Regeneron collaborated with Bayer for the joint development and commercialization of co-formulated combinations of Eylea, rinucumab and nesvacumab for the treatment of ocular diseases or disorders outside the United States.
| Revenue (Most Recent Fiscal Year) | $14.20B |
| Net Income (Most Recent Fiscal Year) | $4.41B |
| PE Ratio (Current Year Earnings Estimate) | 19.02 |
| PE Ratio (Trailing 12 Months) | 15.20 |
| PEG Ratio (Long Term Growth Estimate) | 1.96 |
| Price to Sales Ratio (Trailing 12 Months) | 4.40 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.09 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 12.90 |
| Pre-Tax Margin (Trailing 12 Months) | 34.29% |
| Net Margin (Trailing 12 Months) | 31.37% |
| Return on Equity (Trailing 12 Months) | 15.06% |
| Return on Assets (Trailing 12 Months) | 11.77% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.60 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.09 |
| Inventory Turnover (Trailing 12 Months) | 0.66 |
| Book Value per Share (Most Recent Fiscal Quarter) | $268.50 |
| Earnings per Share (Most Recent Fiscal Quarter) | $10.72 |
| Earnings per Share (Most Recent Fiscal Year) | $38.62 |
| Diluted Earnings per Share (Trailing 12 Months) | $39.68 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 105.99M |
| Free Float | 98.55M |
| Market Capitalization | $62.48B |
| Average Volume (Last 20 Days) | 1.03M |
| Beta (Past 60 Months) | 0.33 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 7.02% |
| Percentage Held By Institutions (Latest 13F Reports) | 83.31% |
| Annual Dividend (Based on Last Quarter) | $3.52 |
| Dividend Yield (Based on Last Quarter) | 0.60% |